Recap: Y-mAbs Therapeutics Q2 Earnings

Shares of Y-mAbs Therapeutics YMAB rose in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 47.52% year over year to ($0.53), which beat the estimate of ($0.64).

Revenue of $10,951,000 higher by 0.00% from the same period last year, which beat the estimate of $7,850,000.

Looking Ahead

Y-mAbs Therapeutics hasn't issued any earnings guidance for the time being.

Y-mAbs Therapeutics hasn't issued any revenue guidance for the time being.

Recent Stock Performance

Company's 52-week high was at $55.22

52-week low: $24.77

Price action over last quarter: Up 11.11%

Company Profile

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!